Raghu Rao is Interim CEO of Sonnet BioTherapeutics Holdings, Inc.. Currently has a direct ownership of 22,356 shares of SONN, which is worth approximately $101,272. The most recent transaction as insider was on Jul 11, 2025, when has been sold 20,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 22.4K
848.9% 3M change
848.9% 12M change
Total Value Held $101,272

Raghu Rao Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 11 2025
BUY
Grant, award, or other acquisition
-
20,000 Added 47.22%
22,356 Common Stock
Dec 11 2023
BUY
Grant, award, or other acquisition
-
373 Added 13.67%
2,356 Common Stock
Oct 27 2023
BUY
Open market or private purchase
-
15,625 Added 48.17%
16,813 Common Stock
Dec 14 2022
BUY
Grant, award, or other acquisition
-
3,770 Added 12.6%
26,140 Common Stock
Dec 15 2021
BUY
Grant, award, or other acquisition
-
14,152 Added 38.75%
22,370 Common Stock
RR

Raghu Rao

Interim CEO
Princeton,, NJ

Track Institutional and Insider Activities on SONN

Follow Sonnet BioTherapeutics Holdings, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SONN shares.

Notify only if

Insider Trading

Get notified when an Sonnet Bio Therapeutics Holdings, Inc. insider buys or sells SONN shares.

Notify only if

News

Receive news related to Sonnet BioTherapeutics Holdings, Inc.

Track Activities on SONN